Overview
AthenaDAO is a decentralized community advancing women's health research, education, and funding — a decentralized science (DeSci) organization that sources, funds, and incubates academic and industry R&D by connecting researchers with legal, strategic, scientific, and market support. It operates as a BioDAO within the Bio Protocol ecosystem, using community-held tokens to govern which projects get funded and how the resulting intellectual property is stewarded.
Women's health is chronically under-funded relative to its disease burden, and AthenaDAO frames the gap as a market opportunity rather than a charity case — pooling community capital to de-risk early translational science that traditional grant pipelines and venture funds routinely skip.
Funding model & track record
Through four funding cohorts the DAO's Web3 community has deployed roughly $1.5 million into science, backing a portfolio that spans early-stage labs, spin-out start-ups, fellowships, and a global network of live research events. Every asset passes the AthenaDAO scientific-review process before capital is committed, and funded IP is held and licensed through the IP-NFT tooling built by Molecule.
Representative research bets have concentrated on ovarian aging — including work on novel therapeutic targets (with Gero), the integrated stress response (ISR) pathway for ovarian follicle survival, and the cGAS–STING inflammatory pathway in reproductive aging — alongside a published data-and-wearables report on ownership and governance of women's health data.
AthenaBIO — from token to equity
In September 2025 AthenaDAO launched AthenaBIO, a dedicated equity vehicle that carries vetted assets through the capital-intensive phases — validation, regulation, and scale — that a community treasury alone cannot underwrite. The vehicle is aiming to raise about $5 million against ~15 assets already cleared by the DAO's scientific review, positioning itself to bridge the biotech "valley of death" between discovery and commercialization.
The founders were candid about why they moved off a pure token model: as one put it, "your token is never going to reflect the value of what you are building" — a recurring tension for DAO tokenomics, where a freely-traded governance token's price drifts away from the value of the underlying work. AthenaDAO's answer was to split the two: keep the DAO for sourcing and governance, and route institutional capital through a separate equity structure.
How Caper approaches this
The token-versus-equity split AthenaBIO reached for is exactly the seam a caper is designed to close. On Caper, contributed capital flows into the caper's own bonding-curve treasury rather than into a free-floating token whose price detaches from the work — value accrues to the treasury itself, and members hold a participation-weighted exit claim on it. Research spending is then authorised the same way governance authorises any spend: a PAYOUT proposal that transfers a chosen currency and amount from the treasury to a lab or researcher once members vote it through. There is no separate equity vehicle to spin up, and voting weight is stake weighted by participation, so the people funding the science keep governance coupled to their exposure.